Results 101 to 110 of about 755,616 (163)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE

open access: yesHemaSphere, 2023
Chakrapani Balijepalli   +4 more
doaj   +1 more source

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX‐1/2 Phase 3 Studies

open access: yes
Clinical &Experimental Allergy, EarlyView.
Gordon Sussman   +15 more
wiley   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao   +4 more
wiley   +1 more source

Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
In treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...
Dominika Écsiová   +6 more
wiley   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar   +6 more
wiley   +1 more source

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

open access: yesFrontiers in Pharmacology
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases (TFKs) are a subfamily of non-receptor protein tyrosine kinases (PTKs) that include five members: TEC, bruton’s tyrosine kinase (BTK), interleukin 2-inducible T-cell kinase ...
Yi Zhang   +13 more
doaj   +1 more source

Scalable Arrayed T‐cell CRISPR Screening in Autologous Tumor Co‐cultures to Prioritize Combination Partners for T‐cell Engagers

open access: yesCurrent Protocols, Volume 6, Issue 11, November 2026.
Abstract T‐cell‐engaging therapies (TCE) have shown clinical promise in hematologic malignancies, but the T‐cell‐intrinsic determinants of TCE‐mediated cytotoxicity remain incompletely defined. This is in part because functional studies in patient‐derived primary samples have been technically challenging.
Keenan Ernste   +9 more
wiley   +1 more source

Salicylic Acid as a Food‐Derived Bioactive Constituent of Tiaoqi Daozhi Decoction: A Potential Functional Food Ingredient to Restoring Gut Barrier Function in Constipation‐Predominant IBS

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Tiaoqi Daozhi Decoction (TQDZD) is a classic formulation composed of eight medicine‐food homologous botanicals. UPLC‐MS/MS profiling identified 1962 non‐redundant compounds in its aqueous extract, predominantly phenolic acids and flavonoids, of which 107 metabolites were systemically bioavailable.
Min Duan   +4 more
wiley   +1 more source

Solution structure and phosphopeptide binding of the SH2 domain from the human Bruton's tyrosine kinase

open access: yes, 2006
[[abstract]]X-linked agammaglobulinemia (XLA) is caused by mutations in the Bruton’s tyrosine kinase (Btk) (Vetrie et al., 1993). The kinase is expressed in most haematopoietic cells, but is selectively down regulated in plasma cells and T-lymphocytes ...
Kuo-Chun Huang;Hsi-Tsung Cheng;Ming-Tao Pai;Shiou-Ru Tzeng;Jya-Wei Cheng   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy